Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressGlobeNewsWire • 08/14/24
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialGlobeNewsWire • 08/13/24
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 07/16/24
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneGlobeNewsWire • 04/25/24
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/10/24
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsGlobeNewsWire • 03/28/24
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/07/24
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewsWire • 01/19/24
Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology ConferenceGlobeNewsWire • 01/17/24
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewsWire • 01/03/24
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceGlobeNewsWire • 11/29/23
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)GlobeNewsWire • 11/28/23
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerGlobeNewsWire • 11/16/23
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationGlobeNewsWire • 10/31/23
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionGlobeNewsWire • 10/26/23
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%GlobeNewsWire • 10/23/23
Apollomics Reports First Half 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 09/28/23
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23